FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)

View source ↗

Summary

The FDA approved a supplemental application for Zarontin (ethosuximide) from Parke-Davis (Pfizer), indicating approval of changes to its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Absence Seizures
• Epilepsy

Drugs mentioned

• ZARONTIN (ethosuximide)

Snippet

SUPPL AP for ZARONTIN (ETHOSUXIMIDE)